David McIntyre Is Appointed CFO of Tessa Therapeutics: Expert Provides 25 Years + of Global, Operational, and Legal Experience

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

December 17, 2020

David McIntyre has been appointed the new Chief Financial Officer of Tessa Therapeutics. The news was announced today.

David McIntyre brings over 25 years of global financial, operational, and legal experience, including over 10 years as Chief Financial Officer of various publicly listed and privately held entities. He joins Tessa from AVITA Medical, Inc. (ASX: AVH,NASDAQ: RCEL), where he served as the Chief Financial Officer.

Before joining AVITA Medical, Mr. McIntyre served as a Partner with Apple Tree Partners (ATP), a multibillion-dollar life science venture capital and growth equity fund. At ATP Mr. McIntyre was responsible for ATP’s medical device portfolio, together with various operating and Board functions, including acting as CFO and Head of Technical Operations at Braeburn, Inc.

“I am pleased to welcome David to Tessa’s leadership team,” said Jeffrey H. Buchalter, President and CEO of Tessa Therapeutics. “His successful experience as a senior executive for both private and public listed companies, and also as a life sciences venture capital firm partner makes him an ideal addition to our leadership team at this pivotal time in Tessa’s journey.”

Prior to ATP, Mr. McIntyre was CFO and COO at HeartWare International, Inc. (previously ASX: HIN;NASDAQ: HTWR) during its transition from pre-clinical stage to commercialization across more than 20 countries. Prior to entering life sciences, Mr McIntyre practiced as a senior attorney at Baker & McKenzie and KPMG specializing in corporate law and held various senior finance roles in multi-national companies.

“The recently published data of Tessa’s Autologous therapy is very impressive, and Tessa’s novel Allogeneic platform shows potential to develop transformative cancer cell therapies,” said Mr. Mclntyre. “I am delighted to join Tessa and I look forward to contributing towards bringing these therapies to patients.”

Mr. McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Master of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.